Channel
@eyang92
On this record: Growth · Engagement · Reactions · Posts · Citations · Cite this entry
7,201subscribers
+119 since we began measuring on 6 August 2026
Risers and fallers across the register · movement among entries of 3,162–10,000.
| Telegram ID | -1003066270123 |
|---|---|
| Type | Channel |
| Username | @eyang92 |
| Created | Between 1 August 2025 and 31 October 2025— estimated from Telegram’s id allocation, not measured. How this range is calculated. |
| First recorded | 6 August 2026 |
| Last confirmed live | 12 August 2026 |
| Measurements held | 4 |
| Confirmed unchanged | 1 time, most recently 12 August 2026 |
| On Telegram | t.me/eyang92 |
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 12 Aug 2026, 12:16 | 7,201 | +57 |
| 9 Aug 2026, 17:51 | 7,144 | +30 |
| 6 Aug 2026, 18:40 | 7,114 | +32 |
| 6 Aug 2026, 03:37 | 7,082 | first reading |
45 posts held, back to 3 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 10 pagesof Telegram’s post history, 20 posts per page.
ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.
ER is defined industry-wide as (forwards + reactions + comments) ÷ views— note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.
| Window | Rolling 30 days · latest post in window 12 August 2026 |
|---|---|
| Posts held | 45 (3 August 2026 – 12 August 2026) |
| Views total | 208,572 |
| Reactions total | 6,454 |
| Forwards / comments | not exposed by the public surface — not measured, not estimated |
| Readings taken | 12 Aug 2026, 02:20 UTC |
Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.
Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.
Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.
5,919 reactions across 43 posts, in 10 distinct kinds. The most used accounts for 54.4% of them.
| Reaction | Count | Share | Share, drawn |
|---|---|---|---|
| ❤ | 3,221 | 54.4% | |
| 👍 | 1,816 | 30.7% | |
| 👏 | 353 | 5.96% | |
| 🔥 | 228 | 3.85% | |
| 🤣 | 99 | 1.67% | |
| 😱 | 85 | 1.44% | |
| 🎉 | 48 | 0.811% | |
| 💯 | 38 | 0.642% | |
| 😁 | 30 | 0.507% | |
| 😭 | 1 | 0.017% |
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 45 of the 45 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 6,454reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 45 most recent posts we hold, published 3 August 2026 to 12 August 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
지난 며칠간은 바이오, 광통신이 강했습니다 오늘은 화장품, 전력기기, 반도체가 강하네요 전닉 레버리지 쏠림 이후, 섹터별 순환매가 들어가는 상황입니다 물론 일부 초고수 트레이더 분들은 가능하겠지만 함부로 주도주 올라타겠다고 사팔사팔했다가는 돈이 녹을 것 같습니다 그냥 자신이 믿는 종목 눌러앉는 게 최선이라고 생각합니다. 예전과 달리 호재는 가격에 적극 반영해주고 있고, 시장상황은 많이 나아졌다고 보여집니다. 급할 필요 없습니다. 모두 화이팅입니다
👍68❤15
<기사 해석> 면역항암제 이후(Post-PD1) 흑색종 적응증으로 RP1이라는 약물이 니볼루맙 병용으로 가속 승인받음 아직 확증 승인은 아님 <인사이트> 1. 흑색종 2차 시장 - 미충족 수요 흑색종 2차 시장이 얼마나 미충족 수요가 큰지 알 수 있음 RP1+니볼루맙 병용으로 ORR 24.2%밖에 안되는 걸로 가속 승인받았기 때문 게다가 RP1은 바이러스 용해제로써, 종양내투여라는 제한된 기작임 2. GI-102 GI-102는 단독으로 ORR 25%, 키트루다 병용으로 ORR 40% 게다가 RB1과 달리 종양 내 투여라는 한계점도 없음 키트루다 뿐만 아니라 다른 T Cell 기반 치료제와 병용 가능 FDA Fast Track 지정도 받음 결론 : 1) 흑색종 2차시장 엄청난 미충족 시장 2) RB1은 가속승인 받았으나 한계가 뚜렷하…
❤24👍11👏1
FDA, 레플리뮨의 흑색종 신약 터드리퀘브(RP1, 치료용 종양용해 바이러스 면역치료제) 두 차례 CRL 이후 세번째 심사서 승인 완료…옵디보 병용요법 단독군에서 ORR 24.2% 및 mDoR 14.1개월 데이터로 가속승인, OS 측정하는 확증 3상은 30년 9월까지 진행 계획 https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-replimunes-skin-cancer-drug-2026-08-06/ (출처 : 엄민용님 텔레그램)
❤11👍2
제가 라이브 방송에서는 펩트론 톤을 좀 낮추는 편인데... 여전히 펩트론 확신 변함 없고 부동의 원픽입니다 컨텐츠 전달자로써 살아남기 위해 여러 종목들 말씀드리는겁니다 본계약 컨빅션 여전하고, 터제 포함될거라는 것도 확신합니다 계약은 7조 "이상"으로 서프라이즈 빅딜이 될거라고 생각합니다 (플랫폼 계약에 7조면 미친 수준이죠) 나아가 로열티 뿐만 아니라, CDMO 비즈니스 모델도 가능하다고 생각합니다. (동아시아 상업화 물량 담당) 더 나아가 PT403 - 노보(혹은 다른 빅팜)와의 계약 가능성도 높다고 생각합니다. 여기서 더더 나아가, 스마트데포+IEP+PTAP+루나플랫폼으로 무한 확장도 노려볼 수 있습니다 지금은 제가 미친놈으로 보이시겠지만 조만간 하나씩 증명될거라고 생각합니다. #펩트론
❤225👍91🔥29🤣18🎉8😱3
https://youtube.com/live/VSyEzmdiK1w?feature=share
❤36👍7
7월 18일에 했던 말입니다. 이날 전후로도 비슷한 얘기 계속 했습니다 그나저나 오늘 했제 많이하네요 짜치는거 알고있습니다만 셀프마케팅의 시대니까 양해 부탁드리겠습니다 🙏
👍203❤29🎉10👏8😱8😁7
오늘 밤8시 유튜브 라이브 주제입니다. 1. 에스티팜 좋게보는 이유 (RNA 올릭스/알지노믹스 장점들 간단 설명) (RNA 트렌드 간단 체크) 2. 펩트론 : 수급 및 현상황 체크, PrRP플랫폼, 플랫폼 4개+신약2개+제네릭의 종합 바이오텍, 내가 꿈꾸는 펩트론의 미래 저번에 여러 종목 다뤘다가 시간 조절 실패해서 그냥 앞으로 2개 종목만 다루고 여러 바이오 종목들 Q&A 하려고합니다 감사합니다
❤117🔥19👏10👍7🎉5
펩트론 현재 공매도 역사상 최대 (140만주) 공매도 비율 6%대로 최대주주 최대표와 거의 비슷한 수준 오늘도 장초부터 공매가 누르고 있었는데, 지금 프매가 살짝 매수하니 또 올라주는 모습입니다. 지금 알테오젠의 상승세도 공매 숏커버(프매 순매수) 영향이 커보이는 상황입니다. 펩트론은 공매잔고 코스닥 Top5 수준이고 아직 숏커버 제대로 시작도 안했습니다. #펩트론
❤127🔥39👍8😁6👏5😱4
개인적으로 에스티팜 좋게보고 있습니다. 비록 2분기 실적발표 이후 급락했으나 그 하락 이유는 1) 당시 시장 분위기 : 바이오센티 최악 2) 타 바이오 대비 낮은 하락률을 몰아서 맞음 3) 일회성 비용으로 인한 영업이익 미스 펀더멘털 이슈가 아니었습니다. 위 블로그 글에서 자세히 설명드렸지만, 에스티팜의 펀더멘털은 여전히 견고하다고 생각합니다 그 이유는.. 1) 수주잔고 계속해서 높아지고 있고 2) 수주잔고의 YoY 성장세 35%대 3) 매출/이익 매년 견고한 성장 (YoY +59%, +41%대) 4) 탑라인 성장에 따른 영업레버리지 가능성을 보여주고 있고 (OPM 20%대로 올라옴) 5) 추후 제2올리고 가동률 올라오면 그 성장은 더욱 올라갈거고 6) 무엇보다 RNA 전방산업에 대한 성장은 의심할 여지가 없기 때문입니다. 7) RN…
❤57👍22👏3🤣3
https://blog.naver.com/qhqnf1gh/224373672442
👍35
펩트론 이후 관심종목들 지아이이노베이션, 보로노이, 큐리언트 주가 흐름이 다 좋습니다
❤84👍27👏4
노바렉스 흐름 좋네요 투자 아이디어입니다 여기는 일단 좀 길게 봐야하지 싶습니다 이미 현캐파는 풀로 돌리고 있어서 더이상의 탑라인 성장은 힘들 것 같고 27년말 이후 증설분을 얼마나 빨리 가동률 올리느냐가 관건인 것 같습니다 #노바렉스 #건기식
❤51👍14👏3
Showing the 12 most recent of 45 posts we hold for @eyang92. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Citation-graph rank — 365,959 of 1,151,006entries in the measured graph. A weighted position computed from the forward and mention edges below — republished posts weigh more than named mentions — and recomputed periodically, over the whole graph. Published only as this ordinal position, never as a score: a position is a fact, and a score printed beside one channel’s name would read as a verdict this register does not make. The two counts beneath stay separate for the same reason mentions are never summed with forwards anywhere else on this page — a named-by count costs nothing to manufacture. The top 100 by this measure, or how it is computed.
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 12 August 2026 — this entry's latest reading, not the date you are reading this.
“작업중이양” (@eyang92), 7,201 subscribers as measured 12 August 2026. Telegram Register, tgregister.com/channel/eyang92.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.